创新药概念股短线走弱，南新制药跌超12%，热景生物跌超9%，舒泰神、苑东生物、美迪西跟跌。 ...

Group 1 - The A-share chemical pharmaceutical sector experienced a sharp rise followed by a decline on August 28, with notable drops in stocks such as Nanxin Pharmaceutical and Rejing Bio, both falling over 10% [1] - Other companies in the sector, including Shutaishen, Yuandong Bio, Kanghong Pharmaceutical, and Kangyuan Pharmaceutical, also saw declines [1]

Market Overview - A-shares experienced fluctuations on August 26, with the Shanghai Composite Index down 0.39%, the Shenzhen Component Index up 0.26%, and the ChiNext Index down 0.75% [1] - Total trading volume reached 2.71 trillion CNY, a decrease of over 460 billion CNY compared to the previous day [1] Stock Performance - Out of 5426 stocks, 2804 rose, 90 hit the daily limit up, and 2470 fell [2][3] - The consumer electronics sector showed strong performance, with stocks like GoerTek hitting the daily limit up [3][5] Notable Gainers - Several stocks in the consumer electronics and technology sectors saw significant gains, including: - Haosheng Electronics up 12.12% at 23.49 CNY [4] - Heli Tai up 10.06% at 3.72 CNY [4] - GoerTek up 10.01% at 34.06 CNY [4] - The Huawei supply chain also strengthened, with stocks like Tuowei Information hitting the daily limit up [5] Agricultural Sector - The agriculture sector saw a rise, with Aonong Biological hitting the daily limit up [7] Decliners - The AI chip sector faced adjustments, with Chip Origin falling over 10% after announcing a share transfer price significantly lower than its closing price [8] - Innovative drug concept stocks declined, with Yuandong Biological down over 10% [9][10] Company-Specific News - Chunzong Technology experienced a sharp drop, hitting the limit down after reporting a 44.85% decline in revenue year-on-year for the first half of 2025, resulting in a net loss of 40.02 million CNY [10]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688513 | 苑东生物 | 63.08 | -10.71% | 6.80万 | 4.53亿 | | 300436 | 广生堂 | 138.88 | -8.60% | 17.82万 | 26.02亿 | | 300204 | 舒泰神 | 56.70 | -7.05% | 37.53万 | 22.76亿 | | 003020 | 立方制药 | 35.90 | -6.75% | 17.56万 | 6.58亿 | | 661000E | 翰宇药业 | 27.23 | -5.94% | 120.21万 | 33.59亿 | | 688382 | 益方生物 | 39.97 | -5.24% | 14.78万 | 6.09亿 | | 002940 | 昂利康 | 52.88 | -4.93% | 19.10万 | 10.55 Z | | 600513 | 联环药业 | 24.12 | -4.74% | 44.07万 | 10.96ZZ | | 002826 ...

A股市场创新药板块走低，其中，苑东生物跌超8%，阳光诺和跌超6%，海特生物、广生堂跌超5%，益 方生物、立方制药、康辰药业、昂利康、欧林生物跌超4%。 责任编辑：栎树 | 代码 | 名称 | | 涨幅% ↑ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | | 688513 | 苑东生物 | 1 | -8.86 | 114亿 | 115.73 | | 688621 | 阳光诺和 | | -6.99 | 83.34 乙 | 97.96 | | 300683 | 海特生物 | 1 | -5.87 | 73.20亿 | 135.94 | | 300436 | 广生堂 | 1 | -5.49 | 229亿 | 339.58 | | 688382 | 益方生物-l | | -4.88 | 232亿 | 201.65 | | 003020 | 立方制药 | - | -4.88 | 69.64亿 | 107.81 | | 603590 | 展反约业 | | -4.44 | 80.63亿 | 119.34 | | 002940 | 昂利康 | | -4.31 | ...

每经AI快讯，8月26日，创新药概念股表现低迷，广生堂、苑东生物、阳光诺和、海特生物、热景生 物、凯莱英、立方制药、济民健康等多股跌超5%。 （文章来源：每日经济新闻） ...

Group 1 - The innovative drug sector in the A-share market has experienced a decline [1] - Yuan Dong Biological has dropped over 8% [1] - Sunshine Novo has decreased by more than 6% [1] Group 2 - Hai Te Biological and Guangsheng Tang have both fallen over 5% [1] - Yi Fang Biological, Li Fang Pharmaceutical, Kang Chen Pharmaceutical, Ang Li Kang, and Ou Lin Biological have all seen declines of over 4% [1]

创新药板块午后持续走低，苑东生物跌超8%，申联生物、热景生物跌超6%，广生堂、凯莱英、立方制 药跌超5%。 ...

证券之星消息，8月25日化学制药板块较上一交易日上涨2.53%，舒泰神领涨。当日上证指数报收于 3883.56，上涨1.51%。深证成指报收于12441.07，上涨2.26%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300204 | 部奏神 | 61.00 | 16.17% | 44.55万 | | 26.28亿 | | 300584 | 海辰药业 | 58.95 | 13.61% | 21.72万 | | 12.08亿 | | 300255 | 常山药业 | 53.25 | 12.84% | C 68.39万 | | 35.26 乙 | | 300558 | 贝达药业 | 72.77 | 11.88% | 1 21.40万 | | 14.82亿 | | 688513 | 苑东生物 | 70.65 | 11.72% | 8.11万 | | 5.66亿 | | 603669 | 灵康药业 | 6.26 | 10.02% | 28.18万 | | ...

太平洋8月22日发布研报称，给予苑东生物（688513.SH）买入评级。评级理由主要包括：1）多个产品 市占率领先，深入布局精麻特药；2）研发投入持续增长，重点推进创新药管线。风险提示：创新药研 发不及预期风险；新产品放量不及预期风险；药品带量采购降价风险；医保支付政策调整带来的风险； 地缘政治风险。 （文章来源：每日经济新闻） ...